LG Life Sciences Ltd. announced on Wednesday that it was launching an independently-developed ovulation induction product called Follitrope in the Chinese market. The product will also be introduced in Japan. This move was marked with the signing of an exclusive sales contract between LG Life Sciences Ltd. and Weijian Pharma Group, a player in the China pharmaceuticals market.
According to the company, Follitrope is designed to boost follicle stimulating hormone (FSH). The treatment has been designed using recombinant DNA techniques developed by LG Life Sciences. The company states that this product is unique as compared to its contemporaries in that it offers stable effect and medicinal purity. It claims that the immunological, biological and physicochemical characteristics of this treatment are the same as natural FSH, making Follitrope a safe and effective medication for treating infertility among females.
Speaking on the occasion, LG Life Sciences’ CEO Jung Il-jae said that the signing of this new contract provides an opportune time to the company to promote safer and more effective treatments for treating female infertility using innovative medical techniques. He said that LG Life Sciences, along in partnership with Weijian Pharma Group is committed to providing greater value to its customers in China’s female infertility treatment market.
In October 2014, LG Life Sciences, along with Mochida Pharmaceutical (Japan), signed an agreement to develop and market a biosimilar for Humira, a drug that treats autoimmune disease. While Mochida will carry exclusive rights to develop and sell Humira in its home country, Japan, once the product is commercialized LG Life Sciences will manufacture and supply the final product to the Japanese company.